 | • レポートコード：QYR2104Z1273 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、131ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、化学療法誘発性末梢神経障害（CIPN）治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（カルシウムチャネルα2-デルタリガンド、抗うつ薬、オピオイド、その他）、用途別市場規模（プラチナ剤、タキサン、ビンカアルカロイド、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・化学療法誘発性末梢神経障害（CIPN）治療の市場動向 ・企業の競争状況、市場シェア ・化学療法誘発性末梢神経障害（CIPN）治療の種類別市場規模（カルシウムチャネルα2-デルタリガンド、抗うつ薬、オピオイド、その他） ・化学療法誘発性末梢神経障害（CIPN）治療の用途別市場規模（プラチナ剤、タキサン、ビンカアルカロイド、その他） ・化学療法誘発性末梢神経障害（CIPN）治療の北米市場規模2016-2027（アメリカ、カナダ） ・化学療法誘発性末梢神経障害（CIPN）治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・化学療法誘発性末梢神経障害（CIPN）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・化学療法誘発性末梢神経障害（CIPN）治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・化学療法誘発性末梢神経障害（CIPN）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Aptinyx Inc、Asahi Kasei Pharma Corp、Regenacy Pharmaceuticals、MAKScientific LLC、Metys Pharmaceuticals AG、Nemus Bioscience Inc、PledPharma、Sova Pharmaceuticals Inc、DermaXon LLC、Kineta Inc、Krenitsky Pharmaceuticals Inc、PeriphaGen、Apexian Pharma、WinSanTor、Solasia Pharma K.K.） ・結論 |
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
By region, the United States has the highest share of income, reaching 47.25 percent in 2019.
Market Analysis and Insights: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market
The global Chemotherapy Induced Peripheral Neuropathy Treatment market size is projected to reach US$ 2276.6 million by 2026, from US$ 1477.4 million in 2019, at a CAGR of 6.4% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Chemotherapy Induced Peripheral Neuropathy Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Chemotherapy Induced Peripheral Neuropathy Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Chemotherapy Induced Peripheral Neuropathy Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Chemotherapy Induced Peripheral Neuropathy Treatment market.
Global Chemotherapy Induced Peripheral Neuropathy Treatment Scope and Market Size
Chemotherapy Induced Peripheral Neuropathy Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy Induced Peripheral Neuropathy Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Segment by Application
Platinum Agents
Taxanes
Vinca Alkaloids
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
MAKScientific LLC
Metys Pharmaceuticals AG
PeriphaGen
Apexian Pharma
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Calcium Channel α2-delta Ligands
1.2.3 Antidepressants
1.2.4 Opioids
1.2.5 Others
1.3 Market by Application
1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Platinum Agents
1.3.3 Taxanes
1.3.4 Vinca Alkaloids
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Perspective (2016-2027)
2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Growth Trends by Regions
2.2.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Dynamic
2.3.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
2.3.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
2.3.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
2.3.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Revenue
3.1.1 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Revenue (2016-2021)
3.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue
3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Ratio
3.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue in 2020
3.5 Chemotherapy Induced Peripheral Neuropathy Treatment Key Players Head office and Area Served
3.6 Key Players Chemotherapy Induced Peripheral Neuropathy Treatment Product Solution and Service
3.7 Date of Enter into Chemotherapy Induced Peripheral Neuropathy Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Chemotherapy Induced Peripheral Neuropathy Treatment Breakdown Data by Type
4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size by Type (2016-2021)
4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Type (2022-2027)
5 Chemotherapy Induced Peripheral Neuropathy Treatment Breakdown Data by Application
5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size by Application (2016-2021)
5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (2016-2027)
6.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
6.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2021)
6.2.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2022-2027)
6.2.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2027)
6.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
6.3.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2021)
6.3.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2022-2027)
6.3.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2027)
6.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
6.4.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2016-2021)
6.4.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (2016-2027)
7.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
7.2.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2021)
7.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2022-2027)
7.2.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2027)
7.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
7.3.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2021)
7.3.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2022-2027)
7.3.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2027)
7.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
7.4.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2016-2021)
7.4.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (2016-2027)
8.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
8.2.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
8.3.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region
8.4.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (2016-2027)
9.2 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
9.2.1 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2027)
9.3 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
9.3.1 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2027)
9.4 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
9.4.1 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (2016-2027)
10.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type
10.2.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application
10.3.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country
10.4.1 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Aptinyx Inc
11.1.1 Aptinyx Inc Company Details
11.1.2 Aptinyx Inc Business Overview
11.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.1.4 Aptinyx Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.1.5 Aptinyx Inc Recent Development
11.2 Asahi Kasei Pharma Corp
11.2.1 Asahi Kasei Pharma Corp Company Details
11.2.2 Asahi Kasei Pharma Corp Business Overview
11.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.2.4 Asahi Kasei Pharma Corp Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.2.5 Asahi Kasei Pharma Corp Recent Development
11.3 Regenacy Pharmaceuticals
11.3.1 Regenacy Pharmaceuticals Company Details
11.3.2 Regenacy Pharmaceuticals Business Overview
11.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.3.4 Regenacy Pharmaceuticals Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.3.5 Regenacy Pharmaceuticals Recent Development
11.4 MAKScientific LLC
11.4.1 MAKScientific LLC Company Details
11.4.2 MAKScientific LLC Business Overview
11.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.4.4 MAKScientific LLC Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.4.5 MAKScientific LLC Recent Development
11.5 Metys Pharmaceuticals AG
11.5.1 Metys Pharmaceuticals AG Company Details
11.5.2 Metys Pharmaceuticals AG Business Overview
11.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.5.4 Metys Pharmaceuticals AG Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.5.5 Metys Pharmaceuticals AG Recent Development
11.6 Nemus Bioscience Inc
11.6.1 Nemus Bioscience Inc Company Details
11.6.2 Nemus Bioscience Inc Business Overview
11.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.6.4 Nemus Bioscience Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.6.5 Nemus Bioscience Inc Recent Development
11.7 PledPharma
11.7.1 PledPharma Company Details
11.7.2 PledPharma Business Overview
11.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.7.4 PledPharma Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.7.5 PledPharma Recent Development
11.8 Sova Pharmaceuticals Inc
11.8.1 Sova Pharmaceuticals Inc Company Details
11.8.2 Sova Pharmaceuticals Inc Business Overview
11.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.8.4 Sova Pharmaceuticals Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.8.5 Sova Pharmaceuticals Inc Recent Development
11.9 DermaXon LLC
11.9.1 DermaXon LLC Company Details
11.9.2 DermaXon LLC Business Overview
11.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.9.4 DermaXon LLC Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.9.5 DermaXon LLC Recent Development
11.10 Kineta Inc
11.10.1 Kineta Inc Company Details
11.10.2 Kineta Inc Business Overview
11.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.10.4 Kineta Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.10.5 Kineta Inc Recent Development
11.11 Krenitsky Pharmaceuticals Inc
11.11.1 Krenitsky Pharmaceuticals Inc Company Details
11.11.2 Krenitsky Pharmaceuticals Inc Business Overview
11.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.11.4 Krenitsky Pharmaceuticals Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.11.5 Krenitsky Pharmaceuticals Inc Recent Development
11.12 PeriphaGen
11.12.1 PeriphaGen Company Details
11.12.2 PeriphaGen Business Overview
11.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.12.4 PeriphaGen Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.12.5 PeriphaGen Recent Development
11.13 Apexian Pharma
11.13.1 Apexian Pharma Company Details
11.13.2 Apexian Pharma Business Overview
11.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.13.4 Apexian Pharma Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.13.5 Apexian Pharma Recent Development
11.14 WinSanTor
11.14.1 WinSanTor Company Details
11.14.2 WinSanTor Business Overview
11.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.14.4 WinSanTor Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.14.5 WinSanTor Recent Development
11.15 Solasia Pharma K.K.
11.15.1 Solasia Pharma K.K. Company Details
11.15.2 Solasia Pharma K.K. Business Overview
11.15.3 Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Introduction
11.15.4 Solasia Pharma K.K. Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
11.15.5 Solasia Pharma K.K. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Calcium Channel α2-delta Ligands
Table 3. Key Players of Antidepressants
Table 4. Key Players of Opioids
Table 5. Key Players of Others
Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Regions (2016-2021)
Table 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Regions (2022-2027)
Table 12. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
Table 13. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
Table 14. Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
Table 15. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Players (2016-2021)
Table 18. Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2020)
Table 19. Ranking of Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Chemotherapy Induced Peripheral Neuropathy Treatment Product Solution and Service
Table 23. Date of Enter into Chemotherapy Induced Peripheral Neuropathy Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2016-2021)
Table 27. Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2016-2021)
Table 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 63. Aptinyx Inc Company Details
Table 64. Aptinyx Inc Business Overview
Table 65. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 66. Aptinyx Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 67. Aptinyx Inc Recent Development
Table 68. Asahi Kasei Pharma Corp Company Details
Table 69. Asahi Kasei Pharma Corp Business Overview
Table 70. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 71. Asahi Kasei Pharma Corp Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 72. Asahi Kasei Pharma Corp Recent Development
Table 73. Regenacy Pharmaceuticals Company Details
Table 74. Regenacy Pharmaceuticals Business Overview
Table 75. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 76. Regenacy Pharmaceuticals Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 77. Regenacy Pharmaceuticals Recent Development
Table 78. MAKScientific LLC Company Details
Table 79. MAKScientific LLC Business Overview
Table 80. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 81. MAKScientific LLC Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 82. MAKScientific LLC Recent Development
Table 83. Metys Pharmaceuticals AG Company Details
Table 84. Metys Pharmaceuticals AG Business Overview
Table 85. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 86. Metys Pharmaceuticals AG Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 87. Metys Pharmaceuticals AG Recent Development
Table 88. Nemus Bioscience Inc Company Details
Table 89. Nemus Bioscience Inc Business Overview
Table 90. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 91. Nemus Bioscience Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 92. Nemus Bioscience Inc Recent Development
Table 93. PledPharma Company Details
Table 94. PledPharma Business Overview
Table 95. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 96. PledPharma Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 97. PledPharma Recent Development
Table 98. Sova Pharmaceuticals Inc Company Details
Table 99. Sova Pharmaceuticals Inc Business Overview
Table 100. Sova Pharmaceuticals Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 101. Sova Pharmaceuticals Inc Recent Development
Table 102. DermaXon LLC Company Details
Table 103. DermaXon LLC Business Overview
Table 104. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 105. DermaXon LLC Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 106. DermaXon LLC Recent Development
Table 107. Kineta Inc Company Details
Table 108. Kineta Inc Business Overview
Table 109. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 110. Kineta Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 111. Kineta Inc Recent Development
Table 112. Krenitsky Pharmaceuticals Inc Company Details
Table 113. Krenitsky Pharmaceuticals Inc Business Overview
Table 114. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 115. Krenitsky Pharmaceuticals Inc Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 116. Krenitsky Pharmaceuticals Inc Recent Development
Table 117. PeriphaGen Company Details
Table 118. PeriphaGen Business Overview
Table 119. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 120. PeriphaGen Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 121. PeriphaGen Recent Development
Table 122. Apexian Pharma Company Details
Table 123. Apexian Pharma Business Overview
Table 124. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 125. Apexian Pharma Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 126. Apexian Pharma Recent Development
Table 127. WinSanTor Company Details
Table 128. WinSanTor Business Overview
Table 129. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 130. WinSanTor Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 131. WinSanTor Recent Development
Table 132. Solasia Pharma K.K. Company Details
Table 133. Solasia Pharma K.K. Business Overview
Table 134. Solasia Pharma K.K. Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 135. Solasia Pharma K.K. Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021) & (US$ Million)
Table 136. Solasia Pharma K.K. Recent Development
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type: 2020 VS 2027
Figure 2. Calcium Channel α2-delta Ligands Features
Figure 3. Antidepressants Features
Figure 4. Opioids Features
Figure 5. Others Features
Figure 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application: 2020 VS 2027
Figure 7. Platinum Agents Case Studies
Figure 8. Taxanes Case Studies
Figure 9. Vinca Alkaloids Case Studies
Figure 10. Others Case Studies
Figure 11. Chemotherapy Induced Peripheral Neuropathy Treatment Report Years Considered
Figure 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Regions (2022-2027)
Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Players in 2020
Figure 17. Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue in 2020
Figure 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type (2016-2027)
Figure 23. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application (2016-2027)
Figure 24. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country (2016-2027)
Figure 25. United States Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type (2016-2027)
Figure 29. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application (2016-2027)
Figure 30. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country (2016-2027)
Figure 31. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Region (2016-2027)
Figure 41. China Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Aptinyx Inc Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 61. Asahi Kasei Pharma Corp Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 62. Regenacy Pharmaceuticals Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 63. MAKScientific LLC Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 64. Metys Pharmaceuticals AG Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 65. Nemus Bioscience Inc Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 66. PledPharma Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 67. Sova Pharmaceuticals Inc Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 68. DermaXon LLC Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 69. Kineta Inc Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 70. Krenitsky Pharmaceuticals Inc Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 71. PeriphaGen Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 72. Apexian Pharma Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 73. WinSanTor Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 74. Solasia Pharma K.K. Revenue Growth Rate in Chemotherapy Induced Peripheral Neuropathy Treatment Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
世界の化学療法誘発性末梢神経障害（CIPN）治療市場規模・現状・予測（2021年-2027年） CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemother…- 世界の末梢神経障害治療市場規模・現状・予測（2021年-2027年） Peripheral neuropathy is a set of symptoms caused by any damage to the nerves that are away from the brain and spinal cord. Peripheral neuropathy is not a single, homogenous disease, but it is a mix of different clinical presentations, natural histories, and pathology. Market Analysis and Insights: …
- 世界の末梢神経障害治療市場規模・現状・予測（2021年-2027年） Peripheral neuropathy is a set of symptoms caused by any damage to the nerves that are away from the brain and spinal cord. Peripheral neuropathy is not a single, homogenous disease, but it is a mix of different clinical presentations, natural histories, and pathology. Market Analysis and Insights: …
- 世界の糖尿病性末梢神経障害治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Diabetic Peripheral Neuropathy Treatment Market The global Diabetic Peripheral Neuropathy Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analys…
- 世界の化学療法薬誘発性肢端紅斑（手足症候群）治療市場規模・現状・予測（2021年-2027年） Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear afte…